Sophia Genetics SA (SOPH)
AI stock analysis · as of Jul 22, 2026
Loading microstructure…
SOPHiA GENETICS is a Swiss cloud-native software company providing the SOPHiA DDM platform for multimodal genomic and clinical data analytics to hospitals, labs, and biopharma. With ~$77M in TTM revenue growing ~19-22% YoY, ~67% gross margins, but persistent operating losses (-$79M net) and negative FCF (-$44M), the core investment question is whether accelerating platform adoption and operating leverage can drive a path to profitability before the ~$70M cash balance requires further dilution.
valuationExpensive on absolute basis (6.7x P/S, 10.2x P/B, negative EV/EBITDA) for a company growing ~20% with -80% operating margins; the multiple only works if growth reaccelerates meaningfully or a clear breakeven path emerges.
This analysis is from Jul 22, 2026. Want the latest on SOPH, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · Revenue growth reaccelerating to ~19-22% YoY ($65M in 2024 to $77M in 2025) with recurring SaaS-like platform dynamics
- · Gross margins holding steady at ~67-69%, consistent with a scalable software model that can produce meaningful operating leverage if opex is contained
- · H.C. Wainwright initiated coverage with a Buy, and the 3-analyst consensus target of $8.00 implies ~23% upside from $6.50
- · Stock has broken out to a 52-week high ($6.50) from a low of $2.92, suggesting improving sentiment and momentum ahead of Q2 results
- · Insider net sells over 180 days reported as $0 in the structured data despite qualitative news of 10b5-1 sales — suggests programmed rather than discretionary distribution
- · $57.5M June equity offering plus $70M cash balance extends runway meaningfully at current burn (~$44M FCF loss)
Bear case
- · Deeply unprofitable: net margin of -102%, operating margin -80%, and TTM net loss of $79M against only $77M revenue — losses are as large as revenue
- · Negative FCF of $44M against $70M cash means ~18 months of runway before another raise is likely, on top of the recent $57.5M dilutive offering
- · Debt-to-equity of 136x signals a very thin equity base — book value has been eroded by cumulative losses, magnifying dilution risk
- · News flow highlights broad insider distribution (CEO, director, multiple 10b5-1 plans) plus an affiliate filing to sell 37,000 founders shares — supply overhang persists
- · Valuation at 6.7x P/S and 10.2x P/B is a premium multiple for a company with sub-25% growth and no visible path to profitability; peers with similar profiles trade at 3-5x sales
- · ROE of -123% and forward P/E of -11.6x reflect a business burning capital, not yet earning it
Catalysts
- · Q2 2026 earnings (next earnings date 2026-08-04) — key data point on growth trajectory and cash burn
- · Continued platform adoption metrics (analytical volume growth, biopharma partnership wins) in interim updates
- · Potential additional sell-side initiations following H.C. Wainwright's Buy
- · Any commentary on path to breakeven or opex discipline that could re-rate the multiple
- · Risk catalyst: another capital raise given ~18-month runway at current burn
Key risks
- · Dilution risk: continued cash burn against a modest cash balance almost certainly requires another equity raise within 12-18 months
- · Growth deceleration — at 19-22%, SOPH is not growing fast enough to justify a premium multiple while burning cash
- · Competitive pressure from larger genomics/bioinformatics platforms (Illumina, Tempus, Veracyte) with deeper resources
- · Insider distribution and affiliate share sales create persistent supply overhang and signal concerns about near-term upside
- · FX and geographic complexity — Swiss-domiciled with revenue spread across Europe, US, LatAm, and APAC
What to watch
- · Q2 2026 earnings on 2026-08-04 — revenue growth rate, gross margin trajectory, and cash burn commentary
- · Cash position updates — any signals of an upcoming raise
- · $6.50 52-week high as resistance; $2.92 low as downside reference
- · Additional analyst initiations or downgrades following H.C. Wainwright's Buy
- · Insider Form 4 filings — whether 10b5-1 selling programs are renewed or expanded
- · Any biopharma partnership announcements or platform expansion news
Key metrics
Price target rationale
Base case $6.75 applies ~7x forward P/S on ~$92M revenue (assuming ~20% growth), roughly in line with current trading. Bull case $9.50 assumes growth acceleration to 25%+ with visible margin improvement, warranting ~9x P/S. Bear case $3.75 reflects a dilutive capital raise and multiple compression to ~4x P/S if burn persists and growth stalls.
On Wall Street's view (mixed): The $8.00 consensus target (~23% upside) is defensible if SOPH sustains 20%+ growth and demonstrates opex discipline, but only 3 analysts cover the name and the target does not adequately price in dilution risk from ongoing cash burn. I see fair value closer to $6-7 in the base case.
What the news says · neutral
SOPH has seen a notable near-term price surge — hitting a 12-month high and gaining 7% in a single session — driven largely by H.C. Wainwright initiating coverage with a Buy rating and strong trading volume ahead of Q2 results. However, the bullish momentum is tempered by a persistent and broad pattern of insider selling, including the CEO, a director, and multiple other insiders executing 10b5-1 sales across June and July, as well as a $57.5M dilutive equity offering that closed in June. An affiliate filing to sell 37,000 founders shares adds further supply-side pressure. The stock appears to be at a critical execution juncture — analysts see growth potential, but insider distribution and dilution are meaningful headwinds that warrant caution.
This analysis is from Jul 22, 2026. Markets move. Get the current read on SOPH and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.